Log in
Log in
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     
Sign up
Or log in with
GoogleGoogle
Twitter Twitter
Facebook Facebook
Apple Apple     

AEGLEA BIOTHERAPEUTICS, INC.

(AGLE)
  Report
Real-time Estimate Cboe BZX  -  11:48:06 2023-02-08 am EST
0.5120 USD   +2.13%
01/18Aeglea Biotherapeutics, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing (form 8-K)
AQ
01/09Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational Efficiency
AQ
01/09Aeglea Biotherapeutics, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
AQ
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisionsFunds 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Aeglea BioTherapeutics, Inc. Appoints Jeffrey M. Goldberg as President, and Member of the Board of Directors

11/30/2022 | 07:01am EST

Aeglea BioTherapeutics, Inc. announced the appointment of Jeffrey M. Goldberg as president, and member of the board of directors effective November 29, 2022. Mr. Goldberg is an accomplished biotech executive with over 25 years of experience leading teams from preclinical discovery through commercialization and previously served as president and chief executive officer of Immunitas Therapeutics. Mr. Goldberg served as president and chief executive officer at Immunitas from 2019-2021.

Under his leadership, Immunitas grew significantly, raised additional capital, and is now in the clinic with its first asset. Prior to joining Immunitas, Mr. Goldberg served as the founding chief operating officer at Akcea where he was responsible for building functions and leading teams across all aspects of the business and eventually grew the team from two employees to over 250 in multiple geographies. Mr. Goldberg played a significant role in the company's initial public offering and fundraising activities, business development and the global launch of two rare disease drugs.

Prior to Akcea, he was the vice president of business operations at Proteostasis Therapeutics, a rare disease company. He also held roles of increasing responsibility at Genzyme, where he led teams through product development and global launches across multiple therapeutic areas. Mr. Goldberg has an MBA and a MS in Chemical Engineering from the Massachusetts Institute of Technology, and a B.S. in Chemical Engineering from Cornell University.

Following the leadership transition and as part of the related evaluation of near-term corporate and clinical development strategy, Aeglea no longer plans to announce interim clinical data from the ongoing Phase 1/2 clinical trial of pegtarviliase in Classical Homocystinuria in the fourth quarter of 2022. Enrollment in the third cohort of the Phase 1/2 trial is ongoing with two patients having completed dosing in the cohort. Additionally, the company has decided not to participate in the Piper Sandler 34th Annual Healthcare Conference and 5th Annual Evercore ISI HealthCONx Conference, both being held November 29-December 1, 2022.

Aeglea looks forward to delivering a clinical update on the pegtarviliase program when more comprehensive data from the third cohort becomes available.


ę S&P Capital IQ 2022
All news about AEGLEA BIOTHERAPEUTICS, INC.
01/18Aeglea Biotherapeutics, Inc. : Notice of Delisting or Failure to Satisfy a Continued Listi..
AQ
01/09Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational ..
AQ
01/09Aeglea Biotherapeutics, Inc. : Regulation FD Disclosure, Financial Statements and Exhibits..
AQ
01/06Aeglea BioTherapeutics Cuts 15% of Workforce, Halts Development Programs; COO to Leave;..
MT
01/06Aeglea Biotherapeutics, Inc. : Change in Directors or Principal Officers (form 8-K)
AQ
01/06Aeglea Biotherapeutics, Inc. Announces Resignation of Leslie Sloan as Chief Operating O..
CI
01/06Aeglea BioTherapeutics Announces Update to Corporate Structure to Increase Operational ..
PR
2022Aeglea Biotherapeutics, Inc. : Amendments to Articles of Inc. or Bylaws; Change in Fiscal ..
AQ
2022Aeglea BioTherapeutics, Inc.(NasdaqGM:AGLE) dropped..
CI
2022Aeglea BioTherapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PR
More news
Analyst Recommendations on AEGLEA BIOTHERAPEUTICS, INC.
More recommendations
Financials (USD)
Sales 2022 2,23 M - -
Net income 2022 -83,8 M - -
Net Debt 2022 - - -
P/E ratio 2022 -0,49x
Yield 2022 -
Capitalization 30,8 M 30,8 M -
Capi. / Sales 2022 13,8x
Capi. / Sales 2023 133x
Nbr of Employees 69
Free-Float 98,0%
Chart AEGLEA BIOTHERAPEUTICS, INC.
Duration : Period :
Aeglea BioTherapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends AEGLEA BIOTHERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 0,50 $
Average target price 2,70 $
Spread / Average Target 439%
EPS Revisions
Managers and Directors
Jeffrey M. Goldberg President, Chief Executive Officer & Director
Jonathan D. Alspaugh Chief Financial & Accounting Officer
Russell J. Cox Chairman
Scott W. Rowlinson Vice President-Research
Mark Bechter Vice President-Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
AEGLEA BIOTHERAPEUTICS, INC.11.42%31
REGENERON PHARMACEUTICALS, INC.6.72%82 172
VERTEX PHARMACEUTICALS5.57%79 200
WUXI APPTEC CO., LTD.13.21%39 533
BIONTECH SE-6.16%34 537
BEIGENE, LTD.13.27%25 942